In a pilot randomized trial in persons with opioid use disorder hospitalized with injection-related infections, an innovative care model combining outpatient parenteral antimicrobial therapy with buprenorphine treatment had similar clinical and drug use outcomes to usual care (inpatient intravenous antibiotic completion) and shortened hospital length of stay by 23.5 days. Clinical Trials Registration: NCT03048643.
|Number of pages||4|
|Journal||Clinical Infectious Diseases|
|State||Published - Mar 3 2020|
Bibliographical noteFunding Information:
This work was supported by the National Institutes of Health National Center for Advancing Translational Sciences through grant UL1TR001998.
Potential conflicts of interest. L. C. F. reports travel support from the University of Vermont. M. R. L. reports consulting fees from Titan and Braeburn and research contract funding to the University of Kentucky to conduct studies funded by Braeburn. S. L. W. reports personal fees from Summit Biosciences, Otsuka, World Meds, and Brainsway; personal fees and nonfinancial support from Braeburn; personal fees and honorarium/travel support from Indivior; medication for a study from Vanda Pharmaceuticals; and travel support from Camurus outside the submitted work. All other authors report no potential conflicts.. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Financial support. This work was supported by the National Institutes of Health National Center for Advancing Translational Sciences through grant UL1TR001998.
© 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: email@example.com.
- injection-drug use
- opioid-related disorders
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases